Immatics Announces Full Year 2024 Financial Results and Business Update
Provided By GlobeNewswire
Last update: Mar 27, 2025
Houston, Texas and Tuebingen, Germany, March 27, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter and full year ended December 31, 2024.
Read more at globenewswire.com
